Nektar Therapeutics (NKTR) had its price target raised by HC Wainwright from $165.00 to $185.00. They now have a "buy" rating on the stock.
Nektar Therapeutics (NKTR) had its price target raised by BTIG Research from $151.00 to $178.00. They now have a "buy" rating on the stock.
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin [Yahoo! Finance]
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin [TheStreet.com]